Related Experiment Video

Updated: Dec 23, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

[COVID-19 in hospitalized children and adolescents]

A Streng1, K Hartmann1, J Armann2

  • 1Kinderklinik und Poliklinik, Universitätsklinikum an der Julius-Maximilians-Universität Würzburg, Würzburg, Deutschland.

Monatsschrift Kinderheilkunde : Organ Der Deutschen Gesellschaft Fur Kinderheilkunde
|April 23, 2020
PubMed

Insights

COVID-19 in hospitalized children typically presents as mild respiratory illness. Severe cases and fatalities are rare, but more data is needed on vulnerable pediatric populations.

Area of Science:

  • Pediatric infectious diseases
  • Virology
  • Public health

Context:

  • Limited clinical knowledge exists regarding COVID-19 course, complications, and treatment in children and adolescents.
  • Early data on pediatric COVID-19 cases are crucial for understanding disease impact.

Purpose:

  • To systematically review current evidence on the clinical presentation of COVID-19 in hospitalized children from Chinese case series.
  • To present initial findings from a German nationwide pediatric hospital survey on COVID-19.

Summary:

  • A review of 12 Chinese case series (6-2143 children) found median ages of 2-7 years, with fever and cough as common symptoms.
  • Lower respiratory tract involvement occurred in 40-100% of cases. Severe courses and fatalities were rare (up to 8%).
  • The German DGPI survey reported 33 hospitalized children, mostly with upper airway infections; 9% required ICU admission.

Impact:

  • This review highlights that COVID-19 in hospitalized children is generally mild, with rare severe outcomes.
  • Identifies critical knowledge gaps concerning neonates, children with chronic conditions, and necessary therapeutic/preventive measures.
  • Provides foundational data for pediatric COVID-19 clinical management and future research directions.
Abstract

Keywords:
Acute respiratory tract infectionCoronavirusPediatricPneumoniaSARS-CoV‑2

More Related Videos

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.8K
Oral Biofilm Sampling for Microbiome Analysis in Healthy Children10:42

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children

Published on: December 31, 2017

17.7K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
133
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
707
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
174
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
177